HeartBeam, Inc.

HeartBeam Partners with Triple Ring Technologies to Co-Develop Telehealth Solution Device

Retrieved on: 
Thursday, March 10, 2022
Health, Medical Devices, Technology, Software, Internet, Cardiology, Hardware, NASDAQ, MI, Medtech, Heart, Time, Collection, Patient, Physician, Risk, Founder, Partnership, FDA, Arrhythmia, Chest pain, Telehealth, Smartphone, Result, ECG, Financial condition report, Triple, Sustainability, Silicon, Analysis, Prevalence, Doctor of Philosophy, Form, Technology, 3D, Coronary artery disease, Environment, Myocardial infarction, Cardiovascular disease, CEO, Federal Food, Drug, and Cosmetic Act, Forward-looking statement, Agreement, Medical imaging, Medical device, Risk management, Triple Ring Technologies, HeartBeam, Inc., TRIPLE RING TECHNOLOGIES, HEARTBEAM, INC.

Triple Ring is an innovative company with an established reputation for working with small and large medtech companies on co-developing successful medical technologies in the marketplace.

Key Points: 
  • Triple Ring is an innovative company with an established reputation for working with small and large medtech companies on co-developing successful medical technologies in the marketplace.
  • Triple Ring has a long history of designing a wide variety of innovative medical devices and underlying technologies, and we are pleased to be working with its medical device team for our telehealth device, said Branislav Vajdic, PhD, Chief Executive Officer and Founder of HeartBeam.
  • The joint effort will be a five-phase expedited device development project to rapidly build and test our 3D vector collection device.
  • Triple Ring is pleased to partner with HeartBeam to develop the integral medical device that is part of their complete Telehealth solution for the detection of heart attacks outside of a medical institution, said Joe Heanue, CEO of Triple Ring Technologies.

HeartBeam Partners with LIVMOR for Cloud Based Remote Monitoring Portal

Retrieved on: 
Wednesday, February 2, 2022
Medical Devices, Health, Technology, Hospitals, Software, Cardiology, Diagnosis, Coronary artery disease, ECG, Forward-looking statement, Risk, Patient, Arrhythmia, MI, NASDAQ, Conditional sentence, Founder, Physician, Result, Goal, Form, 3D, Technology, Partnership, Financial condition report, Prevalence, Biomarker, Emergency department, Cardiovascular disease, RPM, Analysis, Doctor of Philosophy, Time, FDA, Risk management, Medical imaging, LIVMOR, HeartBeam, Inc., LIVMOR, HEARTBEAM, INC.

Under the terms of the agreement LIVMOR will develop a HeartBeam branded version, the HeartBeam Platform, of the LIVMOR RPM platform customized for HeartBeam products, with senior executives of both companies supervising the project.

Key Points: 
  • Under the terms of the agreement LIVMOR will develop a HeartBeam branded version, the HeartBeam Platform, of the LIVMOR RPM platform customized for HeartBeam products, with senior executives of both companies supervising the project.
  • LIVMOR has successfully developed a patient-engaging remote monitoring system of critical physiological biomarkers which we believe can be adapted to utilize with our Emergency Department software solution for more accurate MI detection.
  • We look forward to working with the team at LIVMOR to ready our software for submission to the FDA later this year.
  • While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change.